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Abstract
Septic shock is a severe disease state characterised by the body’s life threatening response to infection. Complex
interactions between endothelial cells and circulating monocytes are responsible for microvasculature dysfunction
contributing to the pathogenesis of this syndrome. Here, we intended to determine whether microparticles derived from
activated monocytes contribute towards inflammatory processes and notably vascular permeability. We found that
endotoxin stimulation of human monocytes enhances the release of microparticles of varying phenotypes and mRNA
contents. Elevated numbers of LPS-induced monocytic microparticles (mMP) expressed CD54 and contained higher levels of
transcripts for pro-inflammatory cytokines such as TNF, IL-6 and IL-8. Using a prothrombin time assay, a greater reduction in
plasma coagulation time was observed with LPS-induced mMP than with non-stimulated mMP. Co-incubation of mMP with
the human brain endothelial cell line hCMEC/D3 triggered their time-dependent uptake and significantly enhanced
endothelial microparticle release. Unexpectedly, mMP also modified signalling pathways by diminishing pSrc (tyr416)
expression and promoted endothelial monolayer tightness, as demonstrated by endothelial impedance and permeability
assays. Altogether, these data strongly suggest that LPS-induced mMP have contrasting effects on the intercellular
communication network and display a dual potential: enhanced pro-inflammatory and procoagulant properties, together
with protective function of the endothelium.
Citation: Wen B, Combes V, Bonhoure A, Weksler BB, Couraud P-O, et al. (2014) Endotoxin-Induced Monocytic Microparticles Have Contrasting Effects on
Endothelial Inflammatory Responses. PLoS ONE 9(3): e91597. doi:10.1371/journal.pone.0091597
Editor: Maria A. Deli, Biological Research Centre of the Hungarian Academy of Sciences, Hungary
Received November 18, 2013; Accepted February 11, 2014; Published March 19, 2014
Copyright:  2014 Wen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Health Medical Research Council # 570771, 571014, 1009914, 1028241 and the Rebecca L.
Cooper Medical Research Foundation. The support of the University of Sydney Bridging Support Grant and funding from the Al Kerr Bequest, Sydney Medical
School is also gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors would like to confirm that co-author Dr. Valery Combes is a PLOS ONE Editorial Board member. This does not alter the
authors’ adherence to PLOS ONE Editorial policies and criteria.
* E-mail: beryl.wen@sydney.edu.au
Introduction
Microparticles (MP) are a population of small vesicles derived
from host cell plasma membranes, ranging between 0.2–1 mm in
diameter. First described by Wolf in 1967 as ‘platelet dust’ [1],
these seemingly inert vesicles are present in the circulation of
normal healthy subjects and have since been proposed as
regulators of vascular homeostasis under physiological conditions
[2]. Their enhanced release is triggered by cell injury, activation or
apoptosis and various clinical studies have shown an association
between MP levels and disease severity [3–6].
The MP formation process, named vesiculation, is complex and
yet to be fully deciphered, with different agonists capable of
inducing different MP profiles. However, it is accepted that MP
bear a negatively charged outer leaflet with exposed phosphati-
dylethanolamine and phosphatidylserine (PS), and a positively
charged inner membrane leaflet where phosphatidylcholine and
sphingomyelin almost exclusively reside [7,8]. Being released from
a range of different cell types, MP display phenotypic and cytosolic
compositions that tend to mirror those of their mother cell. This
could account for their active, procoagulant and inflammatory
nature often observed in vascular functional studies [9–12].
Increased levels of circulating MP have been measured in many
disease states and are closely associated with disease severity. For
example, increased levels of MP derived from monocytes were
found in patients with cancer, diabetes and hypertension [3,13]
compared to healthy individuals. Acting as intermediate messen-
gers, monocytic MP (mMP) are able to transfer biologically active
molecules such as IL-1b and caspase-1 to target cells, subsequently
altering the functional capacity of the latter [14,15]. mMP are
capable of inducing endothelial oxidative stress and upregulating
tissue factor and von Willebrand factor expression to trigger
downstream thrombotic events [16]. Additionally, recent studies
have reported that mMP are capable of inducing endothelial
nitrosative stress [17]. Whilst many studies implicate a deleterious
role for mMP, the actual mechanism describing such a role
remains to be confirmed.
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The elevated level of mMP in infectious diseases such as sepsis is
well established yet their participation in the pathophysiology of
sepsis is still being investigated [18,19]. One of the most important
nosocomial diseases, sepsis encompasses a diverse array of
pathological sequelae leading to a death rate of up to 70% in
the USA and 30% in Australia [20,21]. This severe disease state is
attributed more to the dysregulated inflammatory response to
infection than to the infection itself. One of the major neurological
complications is septic encephalopathy, which, in close association
with mortality, can occur in 8 to 71% of patients with sepsis [22–
24]. Despite extensive research in the area of sepsis, severe sepsis
and septic shock, the pathophysiological mechanisms of this
disease state remains poorly understood as evinced by continued
new strategies proposed for sepsis treatment [25,26].
Under normal conditions, the blood vessels have an important
role in maintaining homeostasis by regulating inflammatory
mediators and controlling responses such as vascular tone
modulation and thrombus formation. During sepsis, the endothe-
lium –including that of the blood brain barrier - can undergo
changes in blood flow, permeability and leukocyte trafficking in an
attempt to maintain homeostasis (reviewed in [27]). Under
inflammatory conditions, disturbances to the blood-brain barrier
can alter the conformation of tight junctions leading to a
functionally compromised barrier. Such modifications affecting
monolayer integrity and thus changes in endothelial permeability
lead to the influx of cells, proteins and excess fluids as is observed
in sepsis [28]. The subsequent formation of oedema has the
potential to further compromise microvascular viability and tissue
perfusion, exacerbating the severity of the disease [29]. In addition
to vascular changes during inflammation, circulating blood cells
undergo a series of responses to inflammatory stimuli. Large
numbers of circulating activated monocytes and their ability to
traverse the blood-brain barrier contribute to the pathogenesis of
this disease [30]. Multiple studies indicate that the excessive
release from monocytes and macrophages of pro-inflammatory
cytokines such as IL-1b, IL-6 and TNF [31] is an important
propagating factor in septic shock and may contribute to multiple
organ failure [32]. As monocytes can trigger the inflammatory
response, MP released by them could also participate in the
pathogenesis of septic shock. The pathophysiological role of
monocytes has long been linked with inflammation, especially
through alteration of the endothelial monolayer although their
exact involvement or that of mMP in the disease process has not
been clarified. Additionally, there is limited information on
whether their MP progeny may serve as intermediate mediators
of cell-cell communication and amplify the endothelial cell
response to monocytic activation.
Therefore, we compared mMP with monocytes for contribu-
tions to inflammatory processes. We hypothesised that mMP
generated by endotoxin stimulation of monocytes could directly
elicit significant endothelial changes. In particular, we evaluated
whether mMP disrupted the blood brain barrier and investigated
the subsequent downstream events.
Materials and Methods
Reagents
TNF was obtained from Peprotech (London, UK), LPS (from
Escherichia coli O111:B4) and cytochalasin D from Sigma (Saint
Louis, MO, USA). The following monoclonal antibodies for flow
cytometry were obtained from Beckman Coulter Immunotech
(Marseille, France): anti- human CD54, CD11b and CD14.
Antibodies to HLA-DR were from eBioscience, to CD31 and
those to tissue factor from BD Pharmingen (San Diego, CA, USA).
Annexin V-FITC was from Beckman Coulter. Rabbit anti-pSrc-
family (Tyr416) and mouse anti-Src antibodies were from Cell
Signalling Technologies; mouse-anti-GAPDH (clone 6C5) anti-
body was from Millipore; rabbit anti-ZO-1 antibody was from
Invitrogen and rabbit anti-VE-Cadherin was from Sigma (Saint
Louis, MO, USA). Secondary anti-rabbit IgG conjugated to
DyLight 800 and anti-mouse IgG conjugated to Dylight 680 were
from Cell Signalling Technologies. For microscopy goat-anti-
rabbit Alexa-Fluor 546 IgG and Pro-long mounting medium
containing DAPI were from Invitrogen.
Cell culture
The immortalised monocytic cell line Mono Mac-6 (MM6), a
human cell line with characteristics of mature monocytes, was a
kind gift from Ziegler-Heitbrock [33] and the monoblastic cell line
THP1 was a kind gift from Saunders [34]. Both monocytic cell
lines were maintained in RPMI medium (Invitrogen) supplement-
ed with 10% heat inactivated foetal calf serum (FCS) (Bovogen) at
37uC in 5% CO2.
The human brain microvascular endothelial cell line hCMEC/
D3 [35] was cultured in endothelial cell basal medium-2 (Lonza)
supplemented with 5% FCS, recombinant long R insulin-like
growth factor-1 (R-IGF-1), vascular endothelial growth factor,
ascorbic acid, hydrocortisone, epidermal growth factor human
recombinant and human fibroblast growth factor-B (all from
Lonza). The cells were seeded onto 0.3% collagen coated flasks
and grown at 37uC in 5% CO2.
MP production
Endothelial cells were seeded onto a 0.3% collagen coated 24-
well plate at 66104 cells/ml and grown for 48 hours until 80%
confluence was reached. To better mimic inflammatory conditions
during endotoxic shock, endothelial cells were then stimulated
with TNF (0.2 to 100 ng/ml) for 18 hours.
MM6 and THP1 monocytes were washed and resuspended in
fresh RPMI culture medium, counted and seeded onto a 6-well
plate (16106 cells/ml) and treated with LPS at100 ng/ml for
18 hours at 37uC. Cell viability was assessed by trypan blue assay.
To harvest either endothelial MP (eMP) or monocytic MP
(mMP), supernatant medium from each cultured cell line was
centrifuged at 500 g for 5 minutes at 25uC to pellet cells and the
resulting supernatant was re-centrifuged at 1,200 g for 5 minutes
to remove cell debris. The final MP pellet was obtained after two
further centrifugations at 18,000 g for 45 minutes at 16uC
conducted with washes in between. MP purity was assessed by
flow cytometry.
eMP were labelled with anti-CD105-PE and mMP were stained
with either anti-CD31-FITC or annexin-V-FITC for 45 minutes
in 106 binding buffer and enumerated by flow cytometry on the
Beckman Coulter FC500 using Flow-CountTM fluorospheres as an
internal standard (Beckman Coulter). The MP region was defined
using a FSC-SSC dot plot as previously described [36]. Briefly, the
upper MP region was set using 0.8–1.1 mm latex beads and the
number of fluorescent of events lying within this MP gate was
measured.
Endotoxin detection in MP preparations
Purified MP were analysed for the presence of endotoxin using a
Limulus Amebocyte Lysate Endotoxin Assay Kit purchased from
Lonza. Samples were run according to manufacturer’s instruc-
tions.
Monocytic Microparticles in Endotoxic Shock
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Phenotyping of monocytes and their derived MP
After LPS stimulation, MM6 and THP1 monocytes were
counted, washed and labelled for CD54, CD11b, HLA-DR,
CD14, CD31 and tissue factor expression according to manufac-
turer’s instructions. Isotype-matched controls were used for each
antibody. Following incubation, excess unbound antibodies were
washed away and the cells were suspended in RPMI for flow
cytometry analysis. Mean fluorescence intensity and percentage of
cells positive for each marker were compared to the values
obtained in resting, unstimulated monocytes.
After purification, equal numbers of mMP derived from resting
and LPS-stimulated cells were incubated with 3 mL of antibody
against CD54, CD11b, HLA-DR, CD14, CD31 or tissue factor
for 45 minutes at room temperature in the dark. Isotype-matched
control antibodies were also used. Samples were subjected to flow
cytometry (Beckman Coulter FC500) and results analysed using
CXP software.
Characterisation of monocytes and mMP cytosolic
content
Total RNA from each monocyte or mMP preparation was
extracted using the RNeasy Mini Kit (Qiagen) instructions
followed by incubation with random primers (10% v/v) (Fermen-
tas) at 70uC for 10 minutes. Reverse transcription was performed
using a M-MLV Reverse Transcriptase RNase H- kit (Solis
BioDyne) according the manufacturer’s instructions with the
addition of dNTP (1 mM) (Fermentas) and RNase OUT (2.5% v/
v) (Invitrogen) followed by enzyme heat inactivation for 5 minutes
at 92uC. The resulting synthesised cDNA were probed with
Sensimix (Quantace) and the following RT-PCR primers:
RPL13A (sense: 59-CGCCCTACGACAAGAAAAAG, antisense:
59-CCGTAGCCTCATGAGCTGTT), CD80 (sense: 59-GGA-
CATGAATATATGGCCCG, antisense: 59-CAACACACTCG-
TATGTGCCC), CD86 (sense: 59-ACAGCAGAAGCAGCCA-
AAAT, antisense: 59-CTTGTGCGGCCCATATACTT), tissue
factor (sense: 59- CCGAACAGTTAACCGGAAGA, antisense: 59
-CTTCACAATCTCGTCGGTGA), ICAM-1 (sense: 59-CTCC-
TCTGCTACTCAGAGTT, antisense: 59-CAT ACACCTTC-
CGGTTGTTC), VCAM-1, (sense: 59-ATGCCTGGGAAGAT-
GGTCG, antisense: 59-TCTGGGGTGGTCTCGATTTTA), IL-
6 (sense: 59-TGTAACCATGGACCCAATATTTACC, antisense:
59-AAGACAGTAACAGCTTAAACCTGGAAA), IL-8 (sense:
59-GGAATTGAATGGGTTTGCTAGAAT, antisense: 59-TGT-
GGATCCTGGCTAGCAGACT), TLR-4 (sense: 59-CCAG-
GATGAGGACTGGGTAA, antisense: 59- TACCAGCACGAC-
TGCTCAG), TNF (sense: 59- AGGGCCTGTACCTCATCTA-
CTCCC, antisense: 59-ACCTTGGTCTGGTAGGAGACGGC),
HLA-DR (sense: 59-CCGAGGATTTCGTGTACCAG, anti-
sense: 59- GCACGACCTCTTCTCGGTTA).
The samples were amplified with 40 cycles of denaturation at
94uC for 60 seconds, annealing at 54uC for 45 seconds followed
by an extension at 72uC for 2 minutes using a Rotorgene PCR
machine (Corbett Research).
Clot time measurement
Control normal pooled plasma (Stago Diagnostica, #0678) and
neoplastin (Stago Diagnostica, #0665) were solubilised according
to manufacturer’s instructions. MP derived from non-stimulated
and LPS-treated monocytes were counted and equal numbers
were added to control plasma before being loaded onto the semi-
automated #STart4 coagulometer (Stago Diagnostica). After
30 seconds of incubation at 37uC, an equal volume of neoplastin
was added and the clot formation time was measured.
Co-culture of mMP with human brain endothelial cells
MP derived from either resting or LPS-stimulated MM6 and
THP1 were co-incubated with a confluent monolayer of either
resting or TNF-primed endothelial cells (0.2 ng/ml) at a ratio of
10 mMP: 1 endothelial cell for 18 hours at 37uC for all conditions
unless otherwise stated. mMP supernatants from final ultracentri-
fugations were used as an additional control. eMP were stained
with anti-CD105-PE mAb and quantitatively analysed by flow
cytometry as previously described.
Protein analysis of human brain endothelial cells
Western blots were performed to observe changes in endothelial
protein expression resulting from incubation with mMP. Briefly,
after denaturation in lysis buffer, endothelial cell lysates were
separated on an 8% polyacrylamide gel by electrophoresis and
transfer blotted onto nitrocellulose membrane (Amersham).
Membranes were incubated in Odyssey blocking buffer for 1 hour
at room temperature before being probed for pSrc-family (Tyr
416), Src, ZO-1, VE-cadherin and GAPDH overnight at 4uC. The
membranes were then washed and incubated with fluorescently
conjugated secondary antibodies for 1 hour at room temperature.
Fluorescent protein expression was analysed using the Odyssey
Imaging System (LICOR). pSrc was expressed as the relative
fluorescence after normalisation to Src total. ZO-1 and VE-
cadherin were both normalised against GAPDH.
Impedance studies
Electrode arrays (Applied BioPhysics, #8W1E) were pre-treated
with L-cysteine (10 mM) (Sigma) for 15 minutes, washed twice in
sterile water and then coated with 0.3% collagen for 1 hour.
Endothelial cells were seeded at 1.56105 cells/ml and loaded into
the electrical cell-substrate impedance sensing (ECIS) morpholog-
ical biosensor (Applied Biophysics) at 37uC for a minimum of
48 hours. Once confluence was attained, endothelial cells were
incubated with TNF (0.2 ng/ml) at 37uC for 18 hours. Equal
numbers of mMP purified from resting or LPS (100 ng/ml)
treated monocytes were added to each endothelial cell condition
and loaded onto the ECIS. Impedance readings of the endothelial
monolayer were taken at 10 minute intervals for 48 hours.
Measurement of 70 kDa Dextran Permeability
Endothelial cells were seeded onto 0.4 mm pore size, collagen
coated Transwell inserts in 24 well plates at 36104 cells/ml and
grown until confluent. The experimental inserts were stimulated
with a low dose of TNF (0.2 ng/ml) overnight at 37uC. MP
purified from resting or LPS-treated monocytes were then added
and co-cultured with the endothelial cells for 24 hours at 37uC.
Overnight treatments of hCMEC/D3 with TNF (100 ng/ml) or
1 hour treatments with cytochalasin-D (10 mg/ml) were used as
positive controls for loss of monolayer integrity.
Endothelial culture medium was replaced with 70 kDa FITC-
dextran (1 mg/ml) (Invitrogen) diluted in DMEM without phenol
red (Gibco) in the upper chamber. After gentle resuspension of the
lower chamber, 50 ml samples were removed at times = 0, 45, 90,
150 and 240 minutes and the fluorescence intensity measured on a
Fluostar Optima (BMG Labtech).
Visualisation of endothelial junctions
Purified MP from resting and LPS-stimulated monocytes were
co-cultured with confluent resting or TNF-pre-stimulated endo-
thelial cells at a ratio of 10 mMP:1 endothelial cell overnight at
37uC. Unbound mMP were then removed and endothelial cells
were washed in PBS before fixation with 1% paraformaldehyde
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for 30 minutes at room temperature. Cells were then permeabi-
lised in 0.1% Triton X-100/PBS for 5 minutes, washed and
blocked with 2% BSA/0.1% Triton-X-100/PBS for 1 hour.
Samples were incubated with primary antibodies a-VE-cadherin
or a-ZO-1(1:200 dilution in blocking buffer) for 40 minutes,
washed and fluorescently labelled with Alexa Fluor-546 (1:800
dilution in blocking buffer) overnight at 4uC. Cells were then
washed and mounted in Pro-long gold antifade reagent containing
DAPI. Samples were viewed using the Olympus IX71 deconvolu-
tion fluorescence microscope for wide field images and the Zeiss
LSM 510 Meta Spectral Confocal microscope.
Statistics
Results are shown as mean 6 S.D and were analysed using
GraphPad Prism 5 software. For statistical analyses, the one way
ANOVA followed by the Tukey post-test and the Kruskall Wallis
followed by the Dunn’s test were used. Comparative statistical
analyses between two groups were performed using the Mann
Whitney test.
Results
Enhancement of endothelial and monocytic MP
production by TNF and LPS
Overnight stimulation of endothelial cells with TNF resulted in
a dose-dependent increase in the number of eMP released
(Figure 1A). These endothelial cells shed 1800161645 MP under
resting conditions while stimulation with TNF at 10 ng/ml
significantly increased endothelial vesiculation. Maximal levels of
eMP were induced by TNF 100 ng/ml. In contrast, TNF 0.2 ng/
ml did not significantly modify eMP release levels from basal levels
but was sufficient to upregulate adhesion molecules such as
ICAM-1 and VCAM-1 (personal data and [37,38]). Thus this sub-
optimal concentration was chosen to prime the endothelial cells
without inducing significant eMP release.
LPS treatment of both monocytic cell lines MM6 and THP1
enhanced the release of mMP as detected using anti-CD31 mAb
(Figure 1B, 1D). As all three doses elicited a significant response
from the monocytes, the dose of LPS 100 ng/ml was chosen as a
sufficient concentration for mMP release without significantly
compromising cell viability, as assessed by the trypan blue
exclusion method (data not shown). After MP purification, a
two-fold increase of basal vesiculation was still observed after LPS
stimulation and the final supernatant was mostly free of MP
(Figure 1C). Similarly, LPS treatment of the monocytic cell line
THP1 significantly enhanced mMP release at all three doses tested
(Figure 1D). The dose of LPS 100 ng/ml induced up to a six-fold
increase of basal vesiculation and was chosen as the optimal dose
for mMP release without significantly compromising cell viability.
Surface and cytosolic content profiling of monocytes and
mMP
Endotoxin levels were measured in MP samples purified from
LPS-treated monocytes using a Limulus amebocyte lysate endo-
toxin assay. The level of endotoxin in MP purified from both
resting and LPS-stimulated monocytes were below the detectable
threshold. We also tested several concentrations of LPS between
1 ng/ml and 1 mg/ml, of which the concentration used for
monocytic activation (100 ng/ml) was significantly higher than the
maximum standard provided (1 EU).
After overnight treatment with LPS, MM6 and their derived
MP were characterised for surface antigen expression by flow
cytometry (Figure 2). We observed that similarly to monocytes,
mMP expressed low or non-detectable levels of HLA-DR or
CD106 (VCAM-1, used as a negative control), respectively,
whether or not they were stimulated with LPS. In contrast,
although monocytes had low surface protein expression of PS
indicated by annexin-V binding, up to 45% of mMP were PS-
positive by annexin V labelling. Compared to the surface antigens
tested, monocytes expressed intermediate levels of CD11b, tissue
factor (TF) and CD14. LPS treatment did not significantly
upregulate these antigens, although a higher percentage of LPS
stimulated cells were positive for them compared to unstimulated
monocytes (35% vs. 42% for CD11b, 56% vs. 74%, for TF, 36%
vs. 40% for CD14, respectively for unstimulated vs. LPS treated
monocytes, data not shown). CD80 and CD86 were detected on
16% and 46% of resting monocytes, respectively. Despite the
increased percentage of monocytes expressing CD80 (27.48%) and
CD86 (69%), quantitative expression levels were not modulated by
LPS stimulation. Virtually all (98.3360.19%) monocytes exhibited
high CD31 expression as did their MP progeny. Interestingly,
there was no significant change in the numbers of MP positive for
CD80 and CD86 between MP harvested from resting monocytes
or from LPS stimulated monocytes. The number of CD31-
postitive mMP also did not change with LPS stimulation. LPS was,
however, able to increase the percentage of CD54-positive cells
from 86% to 97%, and to significantly upregulate monocytic
expression of CD54. Moreover, higher numbers of mMP were
CD54-positive when derived from LPS stimulated cells. Similar
results were observed in the more monoblastic THP1 cell line (see
Fig. S1).
The modulation of transcripts for cytokines and surface
molecules upon LPS stimulation was then tested in MM6 and
their derived MP (Figure 3). Amplification of IL-6, IL-8, TLR4,
TF and CD86 mRNA from MM6 cells revealed a significant
accumulation of these mRNAs 18 hours after LPS. mRNAs from
TNF, CD80 and ICAM-1 were detected but no significant
increase in LPS-stimulated cells was observed. The cells did not
contain detectable levels of HLA-DR or VCAM-1, the latter taken
as a negative control (Figure 3A).
Similarly, in MM6- derived mMP, amplification of IL-8, TNF,
CD86 and ICAM-1 mRNA revealed significantly increased levels
of the mRNA sequences upon LPS stimulation of the monocytes.
No significant change was observed between non-stimulated and
LPS-stimulated mMP for IL-6, TF and CD80. TLR4 mRNA
expression appeared to be down regulated in LPS induced mMP.
These mMP also did not express any sign of HLA-DR or VCAM-
1 (Figure 3B).
mMP are procoagulant
MP purified from resting and LPS-stimulated monocytes were
subjected to a prothrombin time assay. Under standard conditions,
normal pooled plasma clotted in 12.760.05 seconds (Figure 4).
The addition of mMP reduced clotting time in a concentration-
dependent manner. More notably, fewer LPS-induced mMP were
needed for a significant reduction in clotting time - 800 MP/ml
(p,0.01) - with further shortening when 8000 MP/ml were added
to the assay system (p,0.01). In contrast, more MP from non-
stimulated monocytes were needed i.e. 8000 MP/ml, before a
significant reduction in clotting time was observed. (p,0.05). At
low MP numbers, i.e. 400 MP/ml, no significant difference was
observed between the procoagulant potential of non-stimulated
and LPS-induced mMP.
mMP bind to endothelial cells and induce their
vesiculation
Supernatant media from unstimulated, TNF-primed or TNF-
stimulated endothelial cell monolayers were analysed for eMP
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release to define the baseline vesiculation levels prior to co-
incubation with mMP. As expected, stimulation of cells with TNF
100 ng/ml significantly increased the numbers of eMP released
while no change was observed in TNF-primed cells (Figure 5A).
Following an overnight incubation with MM6 mMP, the
number of eMP from non-stimulated, TNF-primed and TNF-
stimulated endothelial cells cumulatively rose (Figure 5B). Al-
though adding mMP to resting endothelial cells produced no
change in eMP release compared with untreated endothelial cells,
the co-incubation of mMP with TNF-primed endothelial cells
enhanced the number of eMP shed in comparison to release after
TNF priming alone. As a control, supernatant media from both
non-stimulated and LPS-stimulated mMP final purifications did
not significantly change the number of eMP released compared to
the medium alone. Stimulation of endothelial cells with mMP
from THP1 revealed similar results whereby enhanced eMP
release was observed in all conditions, and was significantly
enhanced when endothelial cells were TNF-primed and treated
with mMP derived from LPS treated THP1. (See Fig. S2).
Effect of mMP on brain endothelium integrity
Protein content of endothelial cells was examined to determine
whether mMP influenced certain endothelial translational or
phosphorylation events. The cytosolic tyrosine kinase Src is known
to be involved in multiple signalling pathways, including control of
endothelial permeability. Therefore we probed for its activated
and phosphorylated form in our endothelial cells. Exposure of
endothelial cells to TNF at 0.2 ng/ml increased pSrc expression
by 20% while TNF at 100 ng/ml increased pSrc expression by
35%. Co-incubation of endothelial cells with mMP resulted in a
diminished expression of pSrc protein in both the resting and TNF
primed conditions (Figure 6). It was also observed that under
resting conditions, non-stimulated mMP limited pSrc expression
more than did LPS-induced mMP; the reverse was true for TNF-
primed endothelial cells.
After endothelial cells reached confluence, the impedance of the
unstimulated endothelial monolayer remained constant for
36 hours (Figure 7A). Upon the addition of mMP (whether or
not LPS-stimulated), the impedance of the monolayer began
increasing after approximately 8 hours of co-incubation. As
expected, TNF pre-stimulation of endothelial cells was associated
with a reduction in impedance within 24 hours (Figure 7B).
Interestingly, the addition of mMP to TNF pre-treated endothelial
cells also increased the impedance level before the TNF began to
take effect, subsequently causing the impedance to gradually drop
at the same rate as the control after approximately 24 hours.
In conjunction with the impedance assay, a permeability assay
was performed. Endothelial cells, with or without TNF, were
incubated either with non-stimulated or LPS-induced mMP before
FITC-dextran 70 kDa was added. The 18 hour incubation of
either non-stimulated or LPS-induced mMP with resting endo-
thelial cells did not change the trans-monolayer passage of dextran
suggesting no detrimental effect on endothelial monolayer integrity
(Figure 7C). Similarly, pre-stimulation of the endothelial mono-
layer with ‘‘priming’’ doses of TNF (Figure 7D) did not change
permeability to dextran. Treatment with TNF (100 ng/ml)
induced a 25% increase in permeability, compared to an 80%
change induced by the positive control cytochalasin D.
Finally, we investigated the potential modification of candidate
junctional proteins by mMP. After co-culture with endothelial
cells, Western blot analysis revealed that there were no significant
Figure 1. Determining optimal agonist concentrations on hCMEC/D3 and monocytes. Endothelial cells and monocytes were stimulated
overnight with varying doses of TNF and LPS, respectively. Induced eMP were measured by flow cytometry using PE-anti-CD105 mAb (A). MP released
from monocytes were counted directly from the cell suspension prior to any purification process using labelling with FITC-anti-CD31 mAb (B). Post
purification, MP from non-stimulated (NS) and LPS-stimulated monocytes were enumerated and the supernatant (SN) from the final centrifugation
process was also checked to ensure clearance of mMP (C). Experiments were performed at least 3 times in triplicates. Data are expressed as mean 6
SD. *p,0.05, **p,0.01 ***p,0.001.
doi:10.1371/journal.pone.0091597.g001
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Figure 2. Monocyte and mMP surface antigen phenotype. Both unstimulated and LPS-stimulated MM6 were stained with anti-CD106, HLA-
DR, CD80, CD86, CD11b, TF, CD14, CD31, CD54 mAb and annexin-V. The mean fluorescence intensity was measured and compared to isotype-
matched controls (left column). mMP were also stained for the same surface antigens to check inheritance from the parent cell. Positively stained MP
were counted and expressed as the number of MP per 106 monocytes (right column). Monocytes with MFI between 0–1, 1–5, and above 10 were
considered as low expressors (top panel), medium expressors (middle panel) and high expressors (bottom panel) respectively. Experiments were
performed at least 3 times in duplicates. Data are expressed as mean 6 SD. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0091597.g002
Figure 3. Cytosolic mRNA profiling of monocytes and mMP.
RNA was extracted from resting (open bars) or stimulated (black bars)
monocytes (A) and their induced MP (B) and the sequences were
amplified using RT-qPCR. Results were taken as the level relative to
expression at resting levels. Experiments were performed at least 3
times in duplicates. Data are expressed as mean 6 SD. *p,0.05,
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0091597.g003
Figure 4. Procoagulant potential of mMP. mMP from resting and
LPS-stimulated cells were added to normal plasma pool and the change
in clotting time measured. Low doses of mMP did not induce any
changes in clotting time. However, higher numbers of mMP induced a
significant reduction in plasma clotting time. LPS-induced MP (black
bars) also appeared to be more procoagulant than MP from resting
monocytes (open bars). Results are representative of 3 independent
experiments performed in duplicates. Data are mean 6 SD. *p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0091597.g004
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changes in the translation of VE-Cadherin protein, whether or not
endothelial cells were treated with mMP (Figure 8A). However,
when the same cell lysates were probed for ZO-1, we observed an
increased expression of ZO-1 protein in endothelial cells treated
with mMP (Figure 8B). This was particularly significant in resting
endothelial cells treated with mMP from LPS stimulated
monocytes. Enhanced ZO-1 expression was also observed in
TNF primed endothelial cells treated with mMP and independent
of whether the mMP were derived from resting or activated
monocytes.
Fluorescence microscopy revealed that confluent endothelial
cells display smooth, continuous and homogenous junctional
staining at the cell-cell contact when stained for VE-Cadherin in
resting conditions (Figure 8C). Treatment with mMP, whether
from resting or LPS-activated monocytes, showed increased
staining in some areas (arrow) and almost no evident of junctional
VE-Cadherin in others (arrow head), despite the endothelium
remaining intact, suggesting a redistribution of the protein rather
than a de novo synthesis. When observing ZO-1 expression,
untreated endothelial displayed a low yet finely defined junctional
staining pattern. Treatment with mMP mildly enhanced the
staining in junctional areas but was noticeably stronger in the
nuclear and cytosolic areas of the endothelial cells, which together
with Western blot data, is suggestive of an increase in ZO-1
protein synthesis.
Discussion
Current literature suggests that MP displaying a particular
phenotype, whether pro- or anti-inflammatory, can transfer these
properties onto their target cells. Based on the data generated in
this work, we propose an alternate view to that of circulating MP
exacerbating disease severity. Our goal was to investigate the
properties of mMP and how they induce functional changes in
brain microvascular endothelial cells in the context of inflamma-
tion and sepsis. By characterising the surface and mRNA profile of
monocytic cell lines and their MP using flow cytometry and RT-
qPCR, we built on this to decipher the functional outcome of the
interactions with human brain microvascular endothelial cells
using flow cytometry, confocal microscopy and trans-endothelial
electrical resistance. This work addresses the vesiculation of these
monocytes in relation to endothelial reactivity and demonstrates
that mMP are inducing differential endothelial gene expression
involved in a pathway considered anti-inflammatory rather than
pro-inflammatory.
Numerous studies have showed that activation of cells instigates
the release of MP [39,40]. Our experimental data confirms that
key stimulants such as TNF and LPS are capable of increasing
release of MP from human brain endothelial and monocytic cell
lines respectively. We then characterised the surface antigens and
cytoplasmic content of mMP to determine whether they had
similar or different properties from the activated mother cell. By
studying a selection of molecules involved in adhesive, coagulatory
and inflammatory processes capable of eliciting downstream
endothelial cell dysfunction, we were able to extend on
Bernimoulin et al.’s observation in the monoblastic THP1, that
different stimuli could induce unique MP proteomic profiles [41].
A surface antigen phenotype comparison between THP1 and
MM6 revealed a similar surface profile between the two cells lines.
LPS treatment of MM6, maturer and phenotypically closer to
circulating monocytes than the monoblastic THP1 [33], enhanced
their expression pro-inflammatory surface markers such as CD80,
CD86 and CD54 as well the expression of pro-inflammatory
RNAs for IL-6, IL-8 and TNF. Examination of MP progeny from
activated MM6 revealed a more pro-inflammatory profile that,
with the exception of IL-6 and TLR4, mirrored their parent cells.
These qualitatively different mMP thus carry potentially important
Figure 5. Interaction and effect of mMP on eMP vesiculation.
Endothelial cells were primed or activated with TNF overnight and the
levels of MP released were checked before co-incubation with mMP to
ensure cells were optimally responsive (A). After co-incubation with
mMP, controls levels of eMP rose cumulatively (B). Non-stimulated mMP
and final SN did not induce any significant changes. Data represents
duplicates of 4 independent experiments. Data are expressed as mean
6 SD. *p,0.05.
doi:10.1371/journal.pone.0091597.g005
Figure 6. mMP induced protein expression in endothelial cells.
Endothelial protein expression of pSrc (Tyr416) and Src were examined
after treatment with mMP. GAPDH was used as a loading control. Non-
stimulated mMP had a more pronounced effect on resting (top left)
rather than TNF-primed endothelial cells (top right). LPS mMP
significantly decreased pSrc expression in both resting and TNF primed
endothelial cells. Neither SN from the final NS or LPS induced mMP
pellet had any effect. Non-stimulated (NS), TNF primed (TNF 0.2 ng/ml)
and activated (TNF 100 ng/ml) endothelial cells are represented by
open, grey and black bars respectively. Actual protein expression of
pSrc, Src and GAPDH are shown in lower panels. Data represent three
independent experiments. Data are mean 6 SD. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0091597.g006
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biological properties. In the same way an activated monocyte
profile can trigger activation of various target cells, the display of
the very same markers by mMP equips them to also trigger
downstream events caused by receptor-ligand interactions. More-
over, the bearing of mRNA by mMP suggests that after binding
with their target cells, MP can act as intermediates of cell-cell
communication and serve to amplify the effect caused solely by the
parent cell [42]. Additionally, recent studies have also described
that not only can MP transfer functional proteins [43], but that
they are even able to convert proteins from the inert to its
inflammatory form [44]. Furthermore, MP have also been
described as a potential protective mechanism by which parent
cells utilise against RNAse degradation to ensure the successful
deliverance of intact microRNAs to target cells [45]. It is
important to note that whilst it is possible that as transport
vehicles, MP could also serve as a platform for further
dissemination of endotoxin in vivo, the MP samples prepared in
this in vitro study were free from detectable endotoxin demonstrat-
ing that the effects we observe are solely due to the MP and not
due to the presence of LPS carried by the MP.
TF is well known to be highly expressed on the surface of
activated monocytes and an important initiator of the coagulation
cascade [9,46,47]. We found that TF was expressed on MM6 and
was up-regulated by LPS stimulation (both surface protein and
mRNA), however the corresponding MP showed little surface
expression but did contain mRNA. We therefore aimed to assess
whether TF and PS could synergistically increase the procoagulant
potential of mMP derived from MM6. The effect on the clotting
time was modestly enhanced by mMP derived from activated cells
compared to resting cells, emphasising the importance of TF in
coagulation. Our data shows that mMP are indeed procoagulant,
however, this procoagulant potentials seems to be mainly TF-
independent and more reliant on the presence of PS at the surface
of the MP.
Of particular interest to this study, was the functional effect
imparted by mMP onto endothelial cells. Various soluble agonists
(including cytokines and other mediators) can augment cell
vesiculation. Enhanced eMP production is known to be a hallmark
of endothelial cell activation [39,48][49]. However, to our
knowledge this study is the first to demonstrate that mMP
themselves, can promote endothelial vesiculation. The higher
numbers of eMP observed here in our in vitro model of brain
inflammation was consistent with increased release of MP during
inflammation observed in clinical studies [3–5]. Previous studies in
vivo have also described worsening of pulmonary and capillary leak
when treated with high numbers eMP [50]. The fact that LPS-
induced mMP can activate endothelial cells and increase their
eMP production to levels higher than those obtained with a
maximal dose of TNF alone, provides further evidence that MP
are not simply inert bystanders, but biologically active communi-
cators that capable of modifying the response of their target cell.
This is also supported by our data (not shown) and other’s [51]
showing that mMP can up-regulate adhesion molecules at the
surface of endothelial cells.
We originally had hypothesised that interactions between MP
produced by activated monocytes and endothelial cells would
consequently result in endothelial cell dysfunction. However, in
our experiments, while endothelial cells showed activation – as
assessed by enhanced eMP release – under the influence of mMP,
measurement of the endothelial impedance showed that these
mMP may produce stabilization rather than breakdown of the
endothelial monolayer. Previous work by Aharon et al. has
demonstrated that ‘microvesicles’ consisting of MP together with
exosomes, are capable of inducing endothelial apoptosis [52].
Figure 7. Effect of mMP on endothelial cell monolayer. Co-incubation of mMP with resting endothelial cells induced an increase in monolayer
impedance (A). Similarly, co-culturing mMP onto pre-stimulated endothelial cells induced raised impedance of the endothelial monolayer whereas
stimulation with TNF alone (or with SN) decreased TEER (B). The SN did not have any effect. After overnight co-culture, mMP did not alter the passage
of FITC-dextran through either resting (C) or TNF-primed endothelial monolayers (D) over 4 hours. Data shown are representative of three
independent experiments. FITC-dextran permeability assays were performed in triplicates and expressed as means 6 SD.
doi:10.1371/journal.pone.0091597.g007
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Such findings, together with our work, suggest that these different
effects could be attributed to the differences between exosomes
and MP – that they are not only distinguishable by size (40–
100 nm vs. 0.1–1 mm) and origin (a-granule secreted vs. plasma
membrane), but also by their effects on target cells. To our
knowledge thus far, the only other MP capable of increasing
impedance are those derived from platelets [53]. Monocytes on
the other hand triggered a decrease of the TEER, suggesting a
monolayer disruption and an opening of endothelial junctions.
The tightening of cell-cell junctions observed here suggests that
mMP, instead of amplifying the inflammatory response as
expected, may be counteracting the deleterious effects of its
mother cell to reduce the severity of endothelial injury. Both
impedance and permeability results complementarily suggest that
the mMP as applied here did not damage the endothelial cell
monolayer.
In conjunction with the increase of impedance, mMP lowered
the endothelial expression of activated Src without affecting levels
of total Src. Src, a member of the non-receptor Src family tyrosine
kinases is expressed in endothelial cells and regulates physiological
functions such as cell adhesion, proliferation and migration [54].
Recent studies have found a strong correlation between the
activation of Src and increased endothelium permeability [55,56],
whereby inhibition of Src prevented junctional protein phosphor-
ylation and thus reduced permeability [57]. By modifying proteins
involved in cell-cell junctions such as zonula occludens-1 and VE-
cadherin, Src can cause gap formation leading to leaky vessels
[58,59]. In our case, mMP lowered the expression of activated Src,
which seems consistent with the increase in impedance suggestive
of a tightening of the monolayer. Such alteration of endothelial Src
expression by mMP demonstrates that the aforementioned change
in endothelial integrity is not solely the result of a direct contact
but also of a signal transduction triggered within the endothelial
cell. Aside from the Src modification demonstrated here, other
studies have also shown that MP derived from LPS-treated
monocytes can alter endothelial expression of signalling proteins
such as ERK1/2 and NF-kB [51]. Src activation controls vascular
permeability whereby a decrease of this activity by mMP is
associated with reduced endothelium permeability.
Looking further downstream, we determined that mMP
modification of endothelial permeability could indeed be attrib-
uted to the assembly or reorganisation of tight junctional proteins.
Whilst no significant changes were observed in ZO-1 expression at
the plasma membrane of cell-cell junction, treatment with mMP
resulted in an accumulation of cytosolic ZO-1. Gilleron et al.
suggest that the Src/ZO-1 relationship may be in part modulated
by connexin 43, a transmembrane gap junction protein [60]. They
report the recruitment of Src to the plasma membrane enhanced
connexin 43/Src interactions whilst simultaneously driving the
dissociation of connexin 43/ZO-1 complexes. Our work suggests
that the mMP-induced diminishment of pSrc allows the retain-
ment of ZO-1 localised at tight junctions whilst also prompting the
protein synthesis of ZO-1. The contributory role of this enhanced
cytosolic ZO-1 is still yet to be determined.
Previous studies have described Src inhibition leading to an
impaired internalisation of VE-Cadherin and thus reduced
permeability [57,61]. Our data suggest that mMP prevent Src
activation, and do not enhance VE-cadherin production. Rather,
Figure 8. mMP modifies endothelial junctional protein expression. After overnight treatment of endothelial cells with mMP, no changes
were observed in the levels of VE-Cadherin protein expression (A). Resting endothelial cells treated with mMP from resting monocytes (NS MP) and
TNF primed endothelial cells treated with mMP from both resting and activated monocytes (LPS MP) displayed significantly higher levels of ZO-1
protein (B). Confocal microscopy revealed a redistribution of VE-Cadherin (C) and upregulation of cytosolic ZO-1 (D) upon mMP treatment. Data
shown are representative of three independent experiments. Bar graphs are expressed as mean 6 SD. Scale bars = 20 mm. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0091597.g008
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mMP trigger junctional protein redistribution with some areas of
the endothelium displaying weaker VE-cadherin signals and others
showing strong recruitment of VE-cadherin at cell peripheries to
reinforce tight junctions, which, in part, could explain the
observed reduction in permeability. Together, our data suggest
that the Src regulated assembly and disassembly of tight junctions
as reported by Dwyer et al. could be a pathway instigated by mMP
[62].
In conclusion, this study is the first in the field of monocyte
biology to indicate that mMP have a protective role despite being
released by monocytes activated within a pathogenic environment.
More broadly, aside from the traditional view of MP as amplifiers
of the pro-inflammatory response, this study has found that LPS-
induced mMP may actually display a dual potential by having a
deleterious intrinsic phenotype but showing beneficial potential by
preventing further inflammatory damage. Whether both potentials
are active at the same time or sequentially and whether the
protective or deleterious effect is dominant remains to be
determined. Though further studies are required to appreciate
where MP stand in the pathophysiology of septic shock, it is clear
these circulating bioactive vesicles have contrasting effects in the
intercellular communication network and in the subsequent
protective function of the endothelium.
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Figure S1 Resting and LPS-stimulated THP1 were
stained with anti-CD106, HLA-DR, CD80, CD86,
CD11b, TF, CD14, CD31, CD54 mAb and annexin-V.
The mean fluorescence intensity was measured and compared to
isotype-matched controls. Monocytes with MFI between 0–1, 1–5,
and above 5 were considered as low expressors (top panel),
medium expressors (middle panel) and high expressors (bottom
panel) respectively. Experiments were performed three times in
duplicates and expressed as mean 6 SD. **p,0.01.
(TIF)
Figure S2 Endothelial cells were TNF-primed or acti-
vated with high dose of TNF overnight and the levels of
MP before treatment with mMP from either resting of
LPS-stimulated THP1. mMP did not significantly alter eMP
release in resting endothelial cells. However, mMP derived from
LPS-stimulated THP1 significantly enhanced eMP release from
TNF-primed endothelium. Non-stimulated mMP did not induce
any significant changes in TNF primed endothelial cells.
Experiments were performed five times in duplicates or triplicates.
Data are mean 6 SD. **p,0.01.
(TIF)
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